JP2015523407A - 多発性硬化症を処置するための併用療法 - Google Patents

多発性硬化症を処置するための併用療法 Download PDF

Info

Publication number
JP2015523407A
JP2015523407A JP2015524803A JP2015524803A JP2015523407A JP 2015523407 A JP2015523407 A JP 2015523407A JP 2015524803 A JP2015524803 A JP 2015524803A JP 2015524803 A JP2015524803 A JP 2015524803A JP 2015523407 A JP2015523407 A JP 2015523407A
Authority
JP
Japan
Prior art keywords
dimethyl fumarate
dose range
teriflunomide
fingolimod
laquinimod
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015524803A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015523407A5 (enExample
Inventor
タイス・ターヴァイ
ロナルト・ルップ
ピーザ・エム・アナセン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Forward Pharma AS
Original Assignee
Forward Pharma AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Forward Pharma AS filed Critical Forward Pharma AS
Publication of JP2015523407A publication Critical patent/JP2015523407A/ja
Publication of JP2015523407A5 publication Critical patent/JP2015523407A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
JP2015524803A 2012-08-03 2013-08-02 多発性硬化症を処置するための併用療法 Pending JP2015523407A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP12179232.9A EP2692343A1 (en) 2012-08-03 2012-08-03 Combination therapy for treatment of multiple sclerosis
EP12179232.9 2012-08-03
US201261712008P 2012-10-10 2012-10-10
US61/712,008 2012-10-10
EP12187939.9A EP2692344A1 (en) 2012-08-03 2012-10-10 Combination therapy for treatment of Multiple sclerosis
EP12187939.9 2012-10-10
PCT/EP2013/066285 WO2014020156A1 (en) 2012-08-03 2013-08-02 Combination therapy for treatment of multiple sclerosis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018107836A Division JP2018150375A (ja) 2012-08-03 2018-06-05 多発性硬化症を処置するための併用療法

Publications (2)

Publication Number Publication Date
JP2015523407A true JP2015523407A (ja) 2015-08-13
JP2015523407A5 JP2015523407A5 (enExample) 2016-09-23

Family

ID=47008405

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015524803A Pending JP2015523407A (ja) 2012-08-03 2013-08-02 多発性硬化症を処置するための併用療法
JP2018107836A Pending JP2018150375A (ja) 2012-08-03 2018-06-05 多発性硬化症を処置するための併用療法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018107836A Pending JP2018150375A (ja) 2012-08-03 2018-06-05 多発性硬化症を処置するための併用療法

Country Status (20)

Country Link
US (2) US20150164849A1 (enExample)
EP (4) EP2692343A1 (enExample)
JP (2) JP2015523407A (enExample)
KR (3) KR20150040338A (enExample)
CN (3) CN104684553A (enExample)
AU (3) AU2013298517A1 (enExample)
CA (2) CA2880742C (enExample)
DK (1) DK2879672T3 (enExample)
EA (1) EA201590166A8 (enExample)
ES (1) ES2674947T3 (enExample)
HR (1) HRP20180939T1 (enExample)
HU (1) HUE038382T2 (enExample)
LT (1) LT2879672T (enExample)
PL (1) PL2879672T3 (enExample)
PT (1) PT2879672T (enExample)
RS (1) RS57567B1 (enExample)
SI (1) SI2879672T1 (enExample)
SM (1) SMT201800380T1 (enExample)
TR (1) TR201808859T4 (enExample)
WO (1) WO2014020156A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015526477A (ja) * 2012-08-22 2015-09-10 ゼノポート，インコーポレイティド メチル水素フマレートの経口剤形およびそのプロドラッグ
JP2023525084A (ja) * 2020-05-06 2023-06-14 アンシス・エスア 多発性硬化症の処置のためのペプチド及び方法

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ608196A (en) 2008-08-19 2014-09-26 Xenoport Inc Prodrugs of methyl, hydrogen fumarate, pharmaceutical compositions thereof, and methods of use
US9504679B2 (en) 2011-12-19 2016-11-29 Bjoern Colin Kahrs Pharmaceutical compositions comprising glitazones and Nrf2 activators
US20130158077A1 (en) 2011-12-19 2013-06-20 Ares Trading S.A. Pharmaceutical compositions
EP2887934A1 (en) 2012-08-22 2015-07-01 XenoPort, Inc. Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects
US10179118B2 (en) 2013-03-24 2019-01-15 Arbor Pharmaceuticals, Llc Pharmaceutical compositions of dimethyl fumarate
WO2014197860A1 (en) 2013-06-07 2014-12-11 Xenoport, Inc. Method of making monomethyl fumarate
US9421182B2 (en) 2013-06-21 2016-08-23 Xenoport, Inc. Cocrystals of dimethyl fumarate
US9416096B2 (en) 2013-09-06 2016-08-16 Xenoport, Inc. Crystalline forms of (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate, methods of synthesis and use
US9999672B2 (en) 2014-03-24 2018-06-19 Xenoport, Inc. Pharmaceutical compositions of fumaric acid esters
MA40982A (fr) * 2014-11-19 2017-09-26 Biogen Ma Inc Formulation de bille pharmaceutique comprenant du fumarate de diméthyle
MA41139A (fr) 2014-12-11 2017-10-17 Actelion Pharmaceuticals Ltd Combinaison pharmaceutique comportant un agoniste sélectif du récepteur sip1
KR102590068B1 (ko) 2014-12-11 2023-10-16 액테리온 파마슈티칼 리미티드 선택적 s1p1 수용체 효능제에 대한 투약 섭생
LT3733712T (lt) 2016-08-15 2023-09-11 Novartis Ag Išsėtinės sklerozės gydymo schemos ir būdai, panaudojant ofatumumabą
JOP20190207A1 (ar) * 2017-03-14 2019-09-10 Actelion Pharmaceuticals Ltd تركيبة صيدلانية تشتمل على بونيسيمود
US11446055B1 (en) 2018-10-18 2022-09-20 Lumoptik, Inc. Light assisted needle placement system and method
TR201820976A2 (tr) * 2018-12-28 2020-07-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Fi̇ngoli̇mod ve bi̇r spazmoli̇ti̇k i̇çeren farmasöti̇k kombi̇nasyonlar
TW202116297A (zh) * 2019-07-03 2021-05-01 西班牙商布爾奴爾法碼有限公司 組合療法之方法、組成物與套組
CN118436777A (zh) * 2019-09-11 2024-08-06 诺华股份有限公司 通过转换疗法治疗rms
US20230099229A1 (en) 2020-03-13 2023-03-30 Reprise Pharmaceuticals, Inc. Methods of treating multiple sclerosis
CN116672325B (zh) * 2023-06-06 2024-09-03 哈尔滨工业大学 一种包覆中性粒细胞膜的聚芬戈莫德纳米前药的制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009510137A (ja) * 2005-10-07 2009-03-12 アディテック・ファルマ・アクチボラゲット フマル酸エステルを含む制御放出医薬組成物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007006307A2 (en) 2005-07-07 2007-01-18 Aditech Pharma Ab Novel salts of fumaric acid monoalkylesters and their pharmaceutical use
HUE030169T2 (en) * 2009-01-09 2017-05-29 Forward Pharma As Pharmaceutical formulation comprising one or more fumaric acid esters in an erosion matrix
HUE025878T2 (en) 2010-02-12 2016-05-30 Biogen Ma Inc Neuroprotection in demyelinating diseases
US20130259856A1 (en) * 2012-03-27 2013-10-03 Teva Pharmaceutical Industries, Ltd. Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009510137A (ja) * 2005-10-07 2009-03-12 アディテック・ファルマ・アクチボラゲット フマル酸エステルを含む制御放出医薬組成物

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GAWRONSKI, K.M. ET AL.: ""Treatment Options for Multiple Sclerosis: Current and Emerging Therapies"", PHARMACOTHERAPY, vol. 30, no. 9, JPN6017019037, September 2010 (2010-09-01), pages 916 - 927, ISSN: 0003565529 *
GOLD, R. ET AL.: "95. "Clinical efficacy of BG-12, an oral therapy, in relapsing-remitting multiple sclerosis: data fr", MULTIPLE SCLEROSIS J., vol. Vol.17，No.10_Suppl., JPN5015008679, 2 November 2011 (2011-11-02), pages 34, ISSN: 0003565528 *
松下拓也 外1名: ""多発性硬化症−治療の現状と展望−"", 日本臨牀, vol. 69, no. 11, JPN6017019038, November 2011 (2011-11-01), JP, pages 2077 - 2086, ISSN: 0003565530 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015526477A (ja) * 2012-08-22 2015-09-10 ゼノポート，インコーポレイティド メチル水素フマレートの経口剤形およびそのプロドラッグ
JP2023525084A (ja) * 2020-05-06 2023-06-14 アンシス・エスア 多発性硬化症の処置のためのペプチド及び方法

Also Published As

Publication number Publication date
AU2018201801B2 (en) 2019-11-21
CN104684553A (zh) 2015-06-03
HK1211210A1 (en) 2016-05-20
EA201590166A1 (ru) 2015-06-30
AU2013298517A1 (en) 2015-03-05
SI2879672T1 (sl) 2018-10-30
CA3107367A1 (en) 2014-02-06
DK2879672T3 (en) 2018-07-30
ES2674947T3 (es) 2018-07-05
CA2880742A1 (en) 2014-02-06
EP3398595A1 (en) 2018-11-07
AU2020201290B2 (en) 2021-08-19
PL2879672T3 (pl) 2018-10-31
LT2879672T (lt) 2018-07-10
US20190091190A1 (en) 2019-03-28
SMT201800380T1 (it) 2018-09-13
AU2020201290A1 (en) 2020-03-12
TR201808859T4 (tr) 2018-07-23
WO2014020156A1 (en) 2014-02-06
EP2692343A1 (en) 2014-02-05
KR20210147083A (ko) 2021-12-06
CN107669668A (zh) 2018-02-09
EA201590166A8 (ru) 2015-10-30
PT2879672T (pt) 2018-07-03
CN113288891A (zh) 2021-08-24
EP2692344A1 (en) 2014-02-05
JP2018150375A (ja) 2018-09-27
CA2880742C (en) 2021-03-16
EP2879672B1 (en) 2018-04-11
RS57567B1 (sr) 2018-10-31
KR20150040338A (ko) 2015-04-14
EP2879672A1 (en) 2015-06-10
US20150164849A1 (en) 2015-06-18
HUE038382T2 (hu) 2018-10-29
AU2018201801A1 (en) 2018-04-05
KR20200142597A (ko) 2020-12-22
HRP20180939T1 (hr) 2018-12-14

Similar Documents

Publication Publication Date Title
JP2018150375A (ja) 多発性硬化症を処置するための併用療法
TWI814744B (zh) 包含acc抑制劑之組合療法
US20100260755A1 (en) Ibudilast and immunomodulators combination
US20130217681A1 (en) Method and composition for weight-gain management
AU2015212613B2 (en) Use of cladribine for treating neuromyelitis optica
WO2011131705A1 (en) Treatment of multiple sclerosis with masitinib
JP6884841B2 (ja) 多発性硬化症を処置するための併用療法
AU2022201030B2 (en) Benzoic acid or a salt and derivative thereof for use in preventing or treating anti-n-methyl-d-aspartate receptor encephalitis
WO2015176069A2 (en) CLEARANCE OF AMYLOID ß
HK1211210B (en) Combination therapy for treatment of multiple sclerosis
UA127031C2 (uk) Комбінована терапія для лікування розсіяного склерозу
Zwick Combination therapy in MS

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20160218

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160801

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160801

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170530

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170810

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20171023

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180206